{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2003"],"condition":["Adenocarcinoma","Colorectal Cancer"],"disease":["Adenocarcinoma","Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2010410"],"location":["United States"],"study_start_month":["12"],"keyword":["Recurrent rectal cancer","Recurrent colon cancer","Irinotecan","Stage IV rectal cancer","Oxaliplatin","Leucovorin","Stage IV colon cancer","Adenocarcinoma of the colon","Cetuximab","Adenocarcinoma of the rectum","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum","description":"This is a randomized phase II study trial that has served as a screening trial to test the increased efficacy of chemotherapy + cetuximab versus chemotherapy alone among patients with untreated, advanced or metastatic colon cancer regardless of tumor status with respect to EGFR.","dates":{"creation":"2003-12-15"},"accession":"2010410","cross_references":{"ClinicalTrials___gov":["NCT00077233"]}}